NCT04348435View on ClinicalTrials.gov

A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs Against COVID-19.

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 14, 2020

Primary Completion Date

May 12, 2021

Study Completion Date

May 12, 2021

Conditions

COVID-19

Interventions

BIOLOGICAL

HB-adMSCs

Hope Biosciences allogeneic adipose-derived mesenchymal stem cells

OTHER

Placebos

Saline

Trial Locations (1)

77478

Hope Biosciences Stem Cell Research Foundation, Sugar Land

All Listed Sponsors

lead

Hope Biosciences Research Foundation

INDUSTRY

NCT04348435 - A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs Against COVID-19. | Biotech Hunter | Biotech Hunter